Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: What is the impact of JAK2 inhibitor therapy?

Leukemia and Lymphoma

Volumn 52, Issue 7, 2011, Pages 1178-1187

  Tibes, Raoul ^a   Mesa, Ruben A ^a  

^a MAYO CLINIC   (United States)

Author keywords

JAK2; myeloproliferative disorders; novel therapy

Indexed keywords

ANTINEOPLASTIC AGENT; AZD 1480; CYT 387; DASATINIB; ERLOTINIB; EVEROLIMUS; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; LESTAURTINIB; LY 2784544; NS 018; PANOBINOSTAT; PEGINTERFERON ALPHA2A; POMALIDOMIDE; RUXOLITINIB; SB 1518; TG 101348; UNCLASSIFIED DRUG;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; BONE MARROW SUPPRESSION; BONE MARROW TUMOR; CLINICAL TRIAL (TOPIC); CYTOPENIA; DEPRESSION; DIARRHEA; DISEASE ASSOCIATION; DRUG INTOXICATION; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG TOLERABILITY; ENZYME SPECIFICITY; FATIGUE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HISTOPATHOLOGY; HUMAN; MUTATIONAL ANALYSIS; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; PATHOGENESIS; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SUBSTITUTION THERAPY; THROMBOCYTHEMIA; THROMBOCYTOPENIA; TREATMENT PLANNING; TREATMENT RESPONSE; WILD TYPE;

ANTINEOPLASTIC AGENTS; HUMANS; JANUS KINASE 2; LEUKEMIA; MUTATION; MYELOPROLIFERATIVE DISORDERS; NEOPLASM STAGING; PRIMARY MYELOFIBROSIS; PROTEIN KINASE INHIBITORS;

EID: 79959591958     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.566952     Document Type: Review

References (99)

1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937-951.
2. Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008;22:437-438. (Pubitemid 351250553)
3. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood 1951;6:372-375.
4. Passamonti F, Rumi E, Arcaini L, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica 2008;93:1645-1651.
5. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009;113:2895-2901.
6. Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international internet-based survey of 1179 MPD patients. Cancer 2007;109:68-76. (Pubitemid 46120195)
7. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004;350:114-124. (Pubitemid 38056222)
8. Di Nisio M, Barbui T, Di Gennaro L, et al. The haematocrit and platelet target in polycythemia vera. Br J Haematol 2007;136:249-259. (Pubitemid 46020752)
9. Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferonalfa- 2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008;112:3065-3072.
10. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005;353:33-45. (Pubitemid 41007805)
11. Barosi G, Elliot MA, Canepa L, et al. Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies. Leuk Lymphoma 2002;43:2301-2307.
12. Mesa RA, Steensma DP, Pardanani A, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003;101:2534-2541. (Pubitemid 36857609)
13. Cervantes F, Alvarez-Larran A, Domingo A, Arellano- Rodrigo E, Montserrat E. Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. Br J Haematol 2005;129:771-775. (Pubitemid 40904527)
14. Lofvenberg E, Wahlin A, Roos G, Ost A. Reversal of myelofibrosis by hydroxyurea. Eur J Haematol 1990;44:33-38. (Pubitemid 20118419)
15. Petti MC, Latagliata R, Spadea T, et al. Melphalan treatment in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2002;116:576-581. (Pubitemid 34178656)
16. Mesa RA, Nagorney DS, Schwager S, Allred J, Tefferi A. Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer 2006;107:361-370.
17. Elliott MA, Chen MG, Silverstein MN, Tefferi A. Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. Br J Haematol 1998;103:505-511. (Pubitemid 28522460)
18. Ballen KK, Shrestha S, Sobocinski KA, et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 2010;16:358-367.
19. Ballen KK, Shrestha S, Sobocinski KA, et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 2010;16:358-367.
20. el-Kassar N, Hetet G, Briere J, Grandchamp B. Clonality analysis of hematopoiesis in essential thrombocythemia: advantages of studying T lymphocytes and platelets. Blood 1997;89:128-134. (Pubitemid 26428186)
21. Harrison CN, Gale RE, Machin SJ, Linch DC. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications [see comments]. Blood 1999;93:417-424. (Pubitemid 29035723)
22. Ash RC, Detrick RA, Zanjani ED. In vitro studies of human pluripotential hematopoietic progenitors in polycythemia vera. Direct evidence of stem cell involvement. J Clin Invest 1982;69:1112-1118. (Pubitemid 12115675)
23. Dai CH, Krantz SB, Means RT Jr, Horn ST, Gilbert HS. Polycythemia vera blood burst-forming units-erythroid are hypersensitive to interleukin-3. J Clin Invest 1991;87:391-396.
24. Axelrad AA, Eskinazi D, Correa PN, Amato D. Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG-rHu MGDF) in essential thrombocythemia. Blood 2000;96:3310-3321.
25. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-1061. (Pubitemid 40386783)
26. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-1148. (Pubitemid 40663494)
27. Levine RL, Wadleigh M, Cools J. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myelofibrosis with myeloid metaplasia. Cancer Cell 2005;7:387-397. (Pubitemid 40544655)
28. Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005;280:22788-22792. (Pubitemid 40853184)
29. Kralovics R, Passamonti F, Buser AS, et al. A gain of function mutation in Jak2 is frequently found in patients with myeloproliferative disorders. N Engl J Med 2005;352:1779-1790. (Pubitemid 40570926)
30. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-1790. (Pubitemid 40570926)
31. Jelinek J, Oki Y, Gharibyan V, et al. JAK2 mutation 1849G4T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 2005;106:3370-3373. (Pubitemid 41609167)
32. Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both 'atypical' myeloproliferative disorders and myelodysplastic syndromes. Blood 2005;106:1207-1209. (Pubitemid 41129580)
33. Scott LM, Campbell PJ, Baxter EJ, et al. The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood 2005;106:2920-2921. (Pubitemid 41510774)
34. Tefferi A, Lasho TL, Schwager SM, et al. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer 2006;106:631-635. (Pubitemid 43157627)
35. Beer PA, Delhommeau F, LeCouedic JP, et al. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood 2010;115:2891-2900.
36. Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment. Leukemia 2008;22:437-438. (Pubitemid 351250553)
37. Campbell PJ, Scott LM, Baxter EJ, Bench AJ, Green AR, Erber WN. Methods for the detection of the JAK2 V617F mutation in human myeloproliferative disorders. Methods Mol Med 2006;125:253-264.
38. Campbell PJ, Griesshammer M, Dohner K, et al. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood 2006;107:2098-2100. (Pubitemid 43289395)
39. Guglielmelli P, Barosi G, Specchia G, et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood 2009;114:1477-1483.
40. Kittur J, Knudson RA, Lasho TL, et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer 2007;109:2279-2284. (Pubitemid 46801558)
41. Palandri F, Ottaviani E, Salmi F, et al. JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients. Leuk Lymphoma 2009;50:247-253.
42. Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010;115:1703-1708.
43. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 2007;21:1952-1959. (Pubitemid 47299969)
44. Tefferi A. Classification, diagnosis, and management of myeloproliferative disorders in the JAK2V617F era. Hematology Am Soc Hematol Educ Program 2006:240-245.
45. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007;356:459-468. (Pubitemid 46193073)
46. Pardanani A, Lasho TL, Finke C, Hanson CA, Tefferi A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia 2007;21:1960-1963. (Pubitemid 47299970)
47. Pietra D, Li S, Brisci A, et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 2008;111:1686-1689. (Pubitemid 351213460)
48. Pardanani A, Levine RL, Lasho TL, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006;108:3472-3476.
49. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006;3:e270.
50. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010;24:1128-1138.
51. Lasho TL, Pardanani A, McClure RF, et al. Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time. Br J Haematol 2006;135:683-687. (Pubitemid 44674079)
52. Vannucchi AM, Pieri L, Bogani C, et al. Constitutively activated and hyper-sensitive basophils in patients with polycythemia vera: role of JAK2V617F mutation and correlation with pruritus. Blood 2008;112(Suppl. 1): Abstract 3714.
53. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Characteristics and clinical correlates of MPL 515W4L/K mutation in essential thrombocythemia. Blood 2008;112:844-847.
54. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers.N Engl J Med 2009;360:2289-2301.
55. Tefferi A, Lim KH, Abdel-Wahab O, et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 2009;23:1343-1345.
56. Tefferi A, Pardanani A, Lim KH, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009;23:905-911.
57. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009;361:1058-1066.
58. Green A, Beer P. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med 2010;362:369-370.
59. Pardanani A, Lasho T, Finke C, Oh ST, Gotlib J, Tefferi A. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia 2010;24:1713-1718.
60. Sanada M, Suzuki T, Shih LY, et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature 2009;460:904-908.
61. Loh ML, Sakai DS, Flotho C, et al. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood 2009;114:1859-1863.
62. Makishima H, Cazzolli H, Szpurka H, et al. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J Clin Oncol 2009;27:6109-6116.
63. Grand FH, Hidalgo-Curtis CE, Ernst T, et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 2009;113:6182-6192.
64. Jones AV, Chase A, Silver RT, et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 2009;41:446-449.
65. Olcaydu D, Harutyunyan A, Jager R, et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 2009;41:450-454.
66. Carbuccia N, Murati A, Trouplin V, et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia 2009;23:2183-2186.
67. Gelsi-Boyer V, Trouplin V, Roquain J, et al. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br J Haematol 2010;151: 365-375.
68. Jager R, Gisslinger H, Passamonti F, et al. Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. Leukemia 2010;24:1290-1298.
69. Pardanani A, Lasho TL, Finke CM, Mai M, McClure RF, Tefferi A. IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. Leukemia 2010;24:1146-1151.
70. Ho K, Valdez F, Garcia R, Tirado CA. JAK2 translocations in hematological malignancies: review of the literature. J Assoc Genet Technol 2010;36:107-109.
71. Mesa RA. Assessing new therapies and their overall impact in myelofibrosis. Hematology Am Soc Hematol Educ Program 2010:115-121.
72. Wernig G, Kharas MG, Okabe R, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 2008;13:311-320. (Pubitemid 351446195)
73. Ma L, Zhao B, Walgren R, et al. Efficacy of LY2784544, a small molecule inhibitor selective for mutant JAK2 kinase, in JAK2 V617F-induced hematologic malignancy models. Blood 2010;116(Suppl. 1): Abstract 4087.
74. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010;363:1117-1127.
75. Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011;29:789-796.
76. Tyner JW, Bumm TG, Deininger J, et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood 2010;115:5232-5240.
77. Verstovsek S, Deeg HJ, Odenike O, et al. Phase 1/2 study of SB1518, a novel JAK2/FLT3 inhibitor, in the treatment of primary myelofibrosis. Blood 2010;116(Suppl. 1): Abstract 3082.
78. Santos FP, Kantarjian HM, Jain N, et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood 2010;115:1131-1136.
79. Shide K, Kameda T, Markovtsov V, et al. Efficacy of R723, a potent and selective JAK2 inhibitor, in JAK2V617F-induced murine MPD model. Blood 2009;114(Suppl. 1): Abstract 3897.
80. Purandare AV, Pardanani A, McDevitt T, et al. Characterization of BMS-911543, a functionally selective small molecule inhibitor of JAK2. Blood 2010;116(Suppl. 1): Abstract 4112.
81. Verstovsek S, Passamonti F, Rambaldi A, et al. Durable responses with the JAK1/ JAK2 inhibitor, INCB018424, in patients with polycythemia vera (PV) and essential thrombocythemia (ET) refractory or intolerant to hydroxyurea (HU). Blood 2010;116(Suppl. 1): Abstract 313.
82. Moliterno AR, Roboz GJ, Carroll M, Luger S, Hexner E, Bensen-Kennedy DM. An open-label study of CEP-701 inpatients with JAK2 V617F-positive polycythemia vera and essential thrombocytosis. Blood 2008;112(Suppl. 1): Abstract 99.
83. Quintas-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 2009;27:5418-5424.
84. Ianotto J-C, Boyer-Perrard F, Demory J-L, et al. Efficacy and safety of Peg-interferon-a2a in myelofibrosis: a study of the FIM and GEM French Cooperative Groups. Blood 2010;116(Suppl. 1): Abstract 4103.
85. Vannucchi AM, Guglielmelli P, Lupo L, et al. A phase ' study of RAD001, a mTOR inhibitor, in patients with myel: final results. Blood 2010;116(Suppl. 1): Abstract 314.
86. Mascarenhas J, Wang X, Rodriguez A, et al. A phase I study of LBH589, a novel histone deacetylase inhibitor in patients with primary myelofibrosis (PMF) and post-polycythemia/essential thrombocythemia myelofibrosis (post-PV/ET MF). Blood 2009;114(Suppl. 1): Abstract 308.
87. Rambaldi A, Dellacasa CM, Salmoiraghi S, et al. A phase 2A study of the histone-deacetylase inhibitor ITF2357 in patients with Jak2V617F positive chronic myeloproliferative neoplasms. Blood 2008;112(Suppl. 1): Abstract 100.
88. Mesa RA, Pardanani AD, Hussein K, et al. Phase1/-2 study of pomalidomide in myelofibrosis. Am J Hematol 2010;85:129-130.
89. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010;363:1117-1127.
90. Pardanani A, Gotlib JR, Jamieson C, et al. Longer-term follow up with TG101348 therapy in myelofibrosis confirms sustained improvement in splenomegaly, disease-related symptoms, and JAK2V617F allele burden. Blood 2010;116(Suppl. 1): Abstract 459.
91. Hexner E, Goldberg JD, Prchal JT, et al. A multicenter, open label phase I/II study of CEP701 (lestaurtinib) in adults with myelofibrosis; a report on phase I: a study of the Myeloproliferative Disorders Research Consortium (MPD-RC). Blood 2009;114(Suppl. 1): Abstract 754.
92. Moliterno AR, Hexner E, Roboz GJ, et al. An open-label study of CEP-701 in patients with JAK2 V617F-positive PV and ET: update of 39 enrolled patients. Blood 2009;114(Suppl. 1): Abstract 753.
93. Pardanani A, George G, Lasho T, et al. A phase I/II study of CYT387, an oral JAK-1/2 inhibitor, in myelofibrosis: significant response rates in anemia, splenomegaly, and constitutional symptoms. Blood 2010;116(Suppl. 1): Abstract 460.
94. Florensa L, Bellosillo B, Arenillas L, et al. LY2784544, a novel JAK2 inhibitor, decreases in vitro growth of hematopoietic human progenitors from JAK2 V617F positive polycythemia vera patients. Blood 2010;116(Suppl. 1): Abstract 5054.
95. Shide K, Nakaya Y, Kameda T, et al. NS-018, a potent novel JAK2 inhibitor, effectively treats murine MPN induced by the Janus Kinase 2 (JAK2) V617F mutant. Blood 2010;116(Suppl. 1): Abstract 4106.
96. Nakaya Y, Naito H, Homan J, et al. Preferential inhibition of an activated form of Janus Kinase 2 (JAK2) by a novel JAK2 inhibitor, NS-018. Blood 2010;116(Suppl. 1) Abstract: 4107.
97. DeAngelo DJ, Tefferi A, Fiskus W, et al. A phase II trial of panobinostat, an orally available deacetylase inhibitor (DACi), in patients with primary myelofibrosis (PMF), post essential thrombocythemia (ET), and post polycythemia vera (PV) myelofibrosis. Blood 2010;116(Suppl. 1): Abstract 630.
98. Begna KH, Mesa RA, Pardanani A, et al. A phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia 2011;25:301-304.
99. Quintas-Cardama A, Levine R, Manshouri T, Kilpivaara O, Kantarjian HM, Verstovsek S. High rates of molecular response after long-term follow-up of patients with advanced essential thrombocythemia (ET) or polycythemia vera (PV) treated with pegylated interferon-alfa-2A (PEG-IFN-a- 2A; PEGASYS). Blood 2010;116(Suppl. 1): Abstract 461.